Mount Sinai researchers discover potential new therapy for lethal metabolomic disease

MEDIA ADVISORY  

FOR IMMEDIATE RELEASE: Cell Metabolism, June 4, 2024

Newswise — Corresponding Author: Isaac Marin-Valencia, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Kayvan R. Keshari, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Bottom Line: Researchers at the Abimael Laboratory of Neurometabolism and the Neurometabolomics & Neuroinformatics core at Mount Sinai have discovered a potential new therapy, improved an existing treatment, and identified a disease biomarker in a mouse model of a lethal neurometabolic disease in humans.

Results: The study revealed that propionate (a short-chain fatty acid that we can consume or produce through the gut microbiota) serves as a major anaplerotic substrate (a biosynthetic or precursor molecule from which other molecules can be generated) in the brain of mice with pyruvate dehydrogenase deficiency (PDHD), a mitochondrial disease that primarily affects the brain of affected children. Supplementation of propionate along with a modified ketogenic diet (a high fat, low-carbohydrate diet) started before conception, continued throughout pregnancy, and post-natally prolonged lifespan and mildly improved neurological outcomes in PDHD mice. Elevated glucose uptake and glycolysis were also observed as indicators of disease progression.

Why the Research Is Interesting: This research uncovers new therapeutic avenues for treating PDHD, a mitochondrial disorder that causes severe neurological impairments and shortens lifespan in affected patients. By identifying propionate as a potential metabolic treatment, the study offers potential for enhancing current treatment protocols for patients.

Who: The study involved a well-defined mouse model of pyruvate dehydrogenase deficiency.

When: The study was published online on June 4, 2024.

What: The research focused on imaging brain glucose metabolism and analyzing the metabolic network in PDHD.

How: Comprehensive imaging techniques, including: magnetic resonance imaging; magnetic resonance spectroscopy; hyperpolarized MRI (highly sensitive imaging to detect labeled chemical compounds in organs in vivo), flourodeoxyglucose positron emission tomography (imaging used to study metabolism of organs in vivo); 14C-autoradiography (imaging used to visualize radioactive chemical compounds in organs); and 13-NMR spectroscopy (imaging through which chemicals are labeled with a special carbon to track where metabolites go in the tissue) were used to map the metabolic network in the PDHD brain.

Study Conclusions: The study concludes that propionate supports brain metabolism in PDHD. When combined with a modified ketogenic diet starting before conception and continuing throughout pregnancy and postnatally, propionate potentially offers promising therapeutic benefits, including extended lifespan and mildly improved neurological function in the mouse model.

What’s Next: The Mount Sinai research team is now focused on determining the highest tolerated does, the optimal timing for administration during brain development, identifying the side effects of chronic exposure, and establishing the therapeutic range in their mouse model of the disease.

Title of the Article: Imaging brain glucose metabolism in vivo reveals propionate as a major anaplerotic substrate in pyruvate dehydrogenase deficiency

Quote from Mount Sinai’s Dr. Isaac Marin-Valencia: “Our findings highlight the role of propionate in sustaining brain metabolism in PDHD. This discovery opens new avenues for therapeutic interventions that could improve the quality of life for patients suffering from this debilitating condition.”

Contact Information: To request a copy of the paper or to schedule an interview with Dr. Isaac Marin-Valencia or Dr. Kayvan R. Keshari, please contact Mount Sinai’s Director of Media and Public Affairs, Elizabeth Dowling, at [email protected] or at 212-241-9200.

###